semaglutide from hers Hims & falls 8% as FDA issues warning letter over compounded weight loss drug Hims & Hers Launches New

Moreover, the SURMOUNTMMO (tirzepatide, NCT05556512) will assess the impact of the dual GLP-1/GIP RA in cardiovascular outcomes and all-cause mortality for people with obesity (without diabetes) when the REDEFINE-3 study will assess the impact of cagrisema in people with obesity (with and without T2DM) and established cardiovascular disease

Soluble fibre can help form soft, bulky stool that is easier to pass, relieving constipation without promoting diarrhoea

Phase 2 trials showed retatrutide achieved greater weight loss (24.2%) than either semaglutide (~15%) or tirzepatide (~22.5%)

The future of GLP-1 reset strategies The science of GLP-1 receptor pharmacology is advancing rapidly